These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19616430)

  • 1. Design of selective Cathepsin inhibitors.
    Bethel PA; Gerhardt S; Jones EV; Kenny PW; Karoutchi GI; Morley AD; Oldham K; Rankine N; Augustin M; Krapp S; Simader H; Steinbacher S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4622-5. PubMed ID: 19616430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elements.
    Ameriks MK; Axe FU; Bembenek SD; Edwards JP; Gu Y; Karlsson L; Randal M; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6131-4. PubMed ID: 19773165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 1.
    Liu H; Tully DC; Epple R; Bursulaya B; Li J; Harris JL; Williams JA; Russo R; Tumanut C; Roberts MJ; Alper PB; He Y; Karanewsky DS
    Bioorg Med Chem Lett; 2005 Nov; 15(22):4979-84. PubMed ID: 16183279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of succinamide peptidomimetic inhibitors of cathepsin S.
    Chatterjee AK; Liu H; Tully DC; Guo J; Epple R; Russo R; Williams J; Roberts M; Tuntland T; Chang J; Gordon P; Hollenbeck T; Tumanut C; Li J; Harris JL
    Bioorg Med Chem Lett; 2007 May; 17(10):2899-903. PubMed ID: 17382545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K.
    Altmann E; Aichholz R; Betschart C; Buhl T; Green J; Irie O; Teno N; Lattmann R; Tintelnot-Blomley M; Missbach M
    J Med Chem; 2007 Feb; 50(4):591-4. PubMed ID: 17256925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.
    Lee-Dutra A; Wiener DK; Arienti KL; Liu J; Mani N; Ameriks MK; Axe FU; Gebauer D; Desai PJ; Nguyen S; Randal M; Thurmond RL; Sun S; Karlsson L; Edwards JP; Jones TK; Grice CA
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2370-4. PubMed ID: 20153648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method.
    Patterson AW; Wood WJ; Hornsby M; Lesley S; Spraggon G; Ellman JA
    J Med Chem; 2006 Oct; 49(21):6298-307. PubMed ID: 17034136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid-phase parallel synthesis and SAR of 4-amidofuran-3-one inhibitors of cathepsin S: effect of sulfonamides P3 substituents on potency and selectivity.
    Ayesa S; Lindquist C; Agback T; Benkestock K; Classon B; Henderson I; Hewitt E; Jansson K; Kallin A; Sheppard D; Samuelsson B
    Bioorg Med Chem; 2009 Feb; 17(3):1307-24. PubMed ID: 19124252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keto-1,3,4-oxadiazoles as cathepsin K inhibitors.
    Palmer JT; Hirschbein BL; Cheung H; McCarter J; Janc JW; Yu ZW; Wesolowski G
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2909-14. PubMed ID: 16546382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazole-based arylalkyne cathepsin S inhibitors. Part II: optimization of cellular potency.
    Ameriks MK; Cai H; Edwards JP; Gebauer D; Gleason E; Gu Y; Karlsson L; Nguyen S; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6135-9. PubMed ID: 19783435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors.
    Cai J; Baugh M; Black D; Long C; Jonathan Bennett D; Dempster M; Fradera X; Gillespie J; Andrews F; Boucharens S; Bruin J; Cameron KS; Cumming I; Hamilton W; Jones PS; Kaptein A; Kinghorn E; Maidment M; Martin I; Mitchell A; Rankovic Z; Robinson J; Scullion P; Uitdehaag JC; Vink P; Westwood P; van Zeeland M; van Berkom L; Bastiani M; Meulemans T
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4350-4. PubMed ID: 20598883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azepanone-based inhibitors of human cathepsin S: optimization of selectivity via the P2 substituent.
    Kerns JK; Nie H; Bondinell W; Widdowson KL; Yamashita DS; Rahman A; Podolin PL; Carpenter DC; Jin Q; Riflade B; Dong X; Nevins N; Keller PM; Mitchell L; Tomaszek T
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4409-15. PubMed ID: 21733692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.
    Cai J; Bennett DJ; Rankovic Z; Dempster M; Fradera X; Gillespie J; Cumming I; Finlay W; Baugh M; Boucharens S; Bruin J; Cameron KS; Hamilton W; Kerr J; Kinghorn E; McGarry G; Robinson J; Scullion P; Uitdehaag JC; van Zeeland M; Potin D; Saniere L; Fouquet A; Chevallier F; Deronzier H; Dorleans C; Nicolai E
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4447-50. PubMed ID: 20594841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methods for computer-aided chemical biology. Part 5: rationalizing the selectivity of cathepsin inhibitors on the basis of molecular fragments and topological feature distributions.
    Ahmed HE; Bajorath J
    Chem Biol Drug Des; 2009 Aug; 74(2):129-41. PubMed ID: 19549075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrazole-based cathepsin S inhibitors with improved cellular potency.
    Wei J; Pio BA; Cai H; Meduna SP; Sun S; Gu Y; Jiang W; Thurmond RL; Karlsson L; Edwards JP
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5525-8. PubMed ID: 17822900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical synthesis of a Cathepsin S inhibitor: route identification, purification strategies, and serendipitous discovery of a crystalline salt form.
    Deng X; Liang JT; Peterson M; Rynberg R; Cheung E; Mani NS
    J Org Chem; 2010 Mar; 75(6):1940-7. PubMed ID: 20155974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
    Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
    J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diazinones as P2 replacements for pyrazole-based cathepsin S inhibitors.
    Ameriks MK; Bembenek SD; Burdett MT; Choong IC; Edwards JP; Gebauer D; Gu Y; Karlsson L; Purkey HE; Staker BL; Sun S; Thurmond RL; Zhu J
    Bioorg Med Chem Lett; 2010 Jul; 20(14):4060-4. PubMed ID: 20541404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important.
    Cai J; Fradera X; van Zeeland M; Dempster M; Cameron KS; Bennett DJ; Robinson J; Popplestone L; Baugh M; Westwood P; Bruin J; Hamilton W; Kinghorn E; Long C; Uitdehaag JC
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4507-10. PubMed ID: 20580231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.